Demo
Close Language Tab
Locate us
Languages
J
JFL Life Sciences Ltd Pharmaceuticals
₹ 14.70 -0.40 (-2.65%)
  • NSE
  • BSE

Overview

  • BSE Code 535469
  • NSE Symbol JFLLIFE
  • ISIN Demat INE0LA901015
  • Book Value (₹) 11.96
  • Face Value (₹) 10.00
  • Market Cap (₹ Cr.) 51.31
  • P/E (TTM) 12.34
  • EPS (TTM) 1.26
  • Div Yield (%) 1.61

Performance

Today’s Low 14.35
Today’s High 15.85

14.70
52W Low 14.35
52W High 37.15

14.70
Open 15.00
Prev. Close 15.10
Volume 36,000.00

Corporate Actions

Jfl Life Sciences Limited - Disclosure under SEBI Takeover Regulations
Apr 28, 2025

SMIRAL ASHWINKUMAR PATEL has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Jfl Life Sciences Limited - Disclosure under SEBI Takeover Regulations
Apr 28, 2025

Jfl Life Sciences Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

About JFL Life Sciences Ltd

JFL Life Sciences Limited was established as JFL Life Sciences Private Limited' on April 25, 2010 as a Private Limited Company. Pursuant to a Special Resolution held on February 10, 2022, Company converted from a Private Limited to Public Limited Company and name of the Company was changed to JFL Life Sciences Limited', on March 3, 2022. the Company manufactures and market pharmaceutical products. Its product portfolio consists of Dry powder injections, Tablets & Capsules (B-Lactam) solid oral dosage form, Tablet and Capsules (general) and Oral Rehydration Solutions (ORS).

Head quartered in Ahmedabad, Gujarat, Company is involved in manufacturing of pharmaceutical products. With market presence in PAN India, products of JFL is supplied to 10 developed and developing countries throughout the World. To maintain its

competitiveness and to further the cause of health care JFL has laid a strong R&D foundation and a FDA approved state of the art manufacturing facility near Ahmedabad.

In August 2022, the Company launched an IPO of 29,78,000 Equity Shares by raising funds aggregating to Rs. 18.16 Crore.

the Company export products to African countries, Middle Eastern countries and CIS countries, mainly through merchant exporters. the Company is registered with the MOH of Kenya, Nigeria, Yemen, Cambodia & Myanmar for manufacturing of a particular product. Few of the products are also registered with Ukraine, Uzbekistan, Kazakhstan (CIS countries) through merchants.

For the purpose of identification equipment / machinery / containers are appropriately labelled to identify the stage of process. In case of tablets, the materials are quarantined after granulation, compression, coating and final packing operations for clearance from Q.A. before pursuing the next stage of process. In case of capsule, the materials are quarantined after mixing, filling and final packing operation for clearance from Q.A. before pursuing the next stage of process. Containers are labelled as UNDER TEST' with details such as name, code number, quantity, no of containers, manufacturer's name, material code no, and material is then quarantined. A Parenteral Drug (LVP, SVP) is defined as one intended for injection through the skin or other external boundary tissue, rather than through the alimentary canal, so that active substances they contain are administered, using gravity or force, directly into a blood vessel, organ, tissue, or lesion.

Founded: 2010
Managing Director: Smiral Ashwinkumar Patel
Address: 309 Satyam Mall Opp Saman Comp, Nr.Vishweshwar Mahadev Mandir, Ahmedabad, Gujarat, 380015,